PubHawk
N Engl J Med May 2025 PMID 40167274

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.

Marc Humbert, Vallerie V McLaughlin, David B Badesch, H Ardeschir Ghofrani, J Simon R Gibbs, Mardi Gomberg-Maitland, Ioana R Preston, Rogerio Souza, Aaron B Waxman, Victor M Moles, Laurent Savale, Carmine Dario Vizza, Stephan Rosenkranz, Yaru Shi, Barry Miller

Full text PDF Download social card

Mentions

173
Peak: 74 in Apr 2025
across 6 sources since Mar 2025

Extended reach

1,323,191
potential audience

Total likes

382

Video views

728

Mentions per month

Mar 2025 – Oct 2025

Where it's discussed

  • X / Twitter122 posts
  • News41 articles
  • Bluesky3 posts
  • Facebook3 posts
  • YouTube2 videos
  • Blogs2 articles

AI synopsis

What people are saying

There are numerous discussions highlighting the impressive findings of the ZENITH trial, such as the 76% reduced risk of death or hospitalization with sotatercept. Posts utilize emphatic language like 'impressive results' and 'game changer' to convey excitement and suggest the study’s findings could alter treatment paradigms in managing high-risk pulmonary arterial hypertension, reflecting the overall enthusiasm and concern over the implications of the therapy.

AgreementModerate agreement

The majority of discussions express support for the findings of the publication, indicating a generally positive reception.

InterestHigh interest

There is a high level of interest evident as many users highlight specific results and methodologies, and even express curiosity about implications for treatment.

EngagementModerate engagement

While some discussions delve into detailed aspects, such as side effects or trial conditions, others are more surface-level, suggesting moderate engagement overall.

ImpactHigh impact

Many participants perceive the publication as significantly impactful, considering it a potential breakthrough in treatment options for patients with pulmonary arterial hypertension.

Abstract in brief

  • Sotatercept significantly improves exercise capacity and reduces clinical worsening in patients with WHO functional class III or IV pulmonary arterial hypertension.
  • In a phase 3 trial involving 172 patients, those taking sotatercept experienced fewer primary endpoint events (death, lung transplantation, or hospitalization) compared to the placebo group, prompting an early end to the trial due to positive efficacy results.
  • Adverse effects from sotatercept were mostly mild, with epistaxis and telangiectasia being the most reported side effects among patients.
Read the full abstract

Top posts

Most liked on X and Bluesky
NEJM
@NEJM · X

New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr08S8K Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://t.co/XSrLcyxVwT Upadacitinib for Giant-Cell Arteritis (SELECT-GCA phase 3 https://t.co/WSsy7mQQLV

May 29, 2025 · 116 likes · 30 shares · 936,087 followers View post →
Muthu Vaduganathan
@mvaduganathan · X

Wow!

Apr 3, 2025 · 100 likes · 31 shares · 9,245 followers View post →
Samuel Hume
@DrSamuelBHume · X

Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv 5. https://t.co/TKT3xJbcDF 6. https://t.co/LCPGEEwcVZ 7. https://t.co/IazDTzuRuz 8. https://t.co/JS85pKMfaW 9. https://t.co/wdrTn03WYv 10.

Apr 24, 2025 · 40 likes · 2 shares · 29,128 followers View post →
Almudena Castro Conde
@almucastro01 · X

IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Mar 31, 2025 · 35 likes · 10 shares · 16,060 followers View post →
Almudena Castro Conde
@almucastro01 · X

Hoy te contaremos en que para mí es el estudio de esta #ACC25 Zenith trial : Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death ‼️Detenido prematuramente ‼️ https://t.co/OgmEmaQIYM

Mar 31, 2025 · 11 likes · 16,060 followers View post →
ガースー＠関節系内科医
@gasu2019koto · X

Sotatercept(アクチビンシグナルを阻害するBio)が最大耐用量の既存治療が入っているPAH患者の死亡・肺移植・増悪入院の複合アウトカムをプラセボより有意に改善したP3。 有効性に差が出たので試験は早期中止。有害事象は毛細血管拡張、PLT低下、Hb上昇、鼻出血、歯肉出血程度 https://t.co/6iOkolEHVE

Apr 10, 2025 · 8 likes · 2,039 followers View post →

All mentions

Anesthesiology Journals
@_Anesthesiology · X

Read a summary of "Sotatercept in patients with pulmonary arterial hypertension at high risk for death," in the October 2025 Science, Medicine, and the Anesthesiologist: https://t.co/97zWfcuzCY https://t.co/zVGMiX1Yf4

Oct 11, 2025 · 2 likes · 1 share · 38,219 followers View post →
Juan Senior
@jsenior64 · X

El que evaluó desenlaces clínicos importantes. https://t.co/mZgTvEvQfw

Oct 1, 2025 · 11,062 followers View post →
Mark
@headass_deadass · X

RT @accpcardprn: It’s #WNW with the recently published results ZENITH in @NEJM. This study found that sotatercept was superior to placebo f…

Aug 30, 2025 · 2 shares · 775 followers View post →
CardioNotion
@CardioNotion · X

5⃣

Jun 20, 2025 · 2 likes · 15,280 followers View post →
STITCHES Medicine - the Best of Medical Research
@medicine.stitches.today · Bluesky

Sotatercept significantly reduces the risk of severe events in high-risk pulmonary arterial hypertension patients compared to placebo. by Humbert M, McLaughlin VV (...) Hoeper MM et 19 al. in N Engl J Med #MedSky

Jun 7, 2025 · 1 like View post →
STITCHES Medicine - the Best of Medical Research
@STITCHESMed · X

Sotatercept significantly reduces the risk of severe events in high-risk pulmonary arterial hypertension patients compared to placebo. by Humbert M, McLaughlin VV (...) Hoeper MM et 19 al. in N Engl J Med https://t.co/rzW54Cnlu6 #MedX #MedResearch

Jun 7, 2025 · 88 followers View post →
Dr. Nazifa Kadery, PharmD, RPh
@dose_of_naz · X

Ph3 ZENITH: #Sotatercept in Patients with #PulmonaryArterialHypertension (#PAH) at High Risk for Death #Merck https://t.co/Rc9DyOtBZO

Jun 1, 2025 · 261 followers View post →
Truthoverdishonesty
@Nigelj08223326 · X

Sotatercept in Patients with Pulmonary Arterial Hypertension https://t.co/qpCnaQcN1D sotatercept resulted in a lower risk of a composite of death from any cause lung transplantation hospitalization (≥24 hours) for worsening PAH than placebo @AskDrShashank @juniorjuri https://t.co/6wsUn9Gd9F

May 31, 2025 · 1 like · 1,607 followers View post →
fausto heredia z.
@drfherediaz · X

RT @LuisZuritaG: Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | New England Journal of Medicine http…

May 30, 2025 · 1 share · 4,356 followers View post →
Luis Zurita G.
@LuisZuritaG · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | New England Journal of Medicine https://t.co/sRnyh7FODz

May 30, 2025 · 4 likes · 1 share · 6,422 followers View post →
จ๋อง
@panupong_mtnd · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 265 followers View post →
Micah Etter MD
@MEtterMD · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 333 followers View post →
INTERNAL MEDICINE
@medicinterna · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 2,462 followers View post →
Arz Lubnan
@tallcedarofleb · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 2,791 followers View post →
Aysel ISLAMLI
@islamliaysel · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 378 followers View post →
Marko
@Markotelomerase · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 64 followers View post →
IAM
@IsaacEmanu58873 · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 15 followers View post →
Sameer Ahmed
@SameerA41115539 · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 997 followers View post →
Wimen
@1a31551c566e43d · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 672 followers View post →
旅人 tabito
@tabibito250 · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | New England Journal of Medicine https://t.co/U7stdUTXFb

May 29, 2025 · 1,072 followers View post →
พาโรม่า! ft.ผับอัลเกิร์ล III
@Fame_PE0810 · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 227 followers View post →
raghav gundavarapu
@DocRaghav · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 208 followers View post →
Jerome HADJADJ
@HadjadjJerome · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 829 followers View post →
Emmanuele
@Biotech2050 · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 6,268 followers View post →
Dr.D.K.P
@DKP37 · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 434 followers View post →
Habib Cissé
@Kissiland_man · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 893 followers View post →
Wei-Guo Ma, MD
@Dr_Ma_of_PUMC · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 2,370 followers View post →
Guillermo
@Guillesuarezc · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 1,665 followers View post →
Vikash Jaiswal
@VikashJaiswalMD · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 350 followers View post →
Juan Pablo
@Jpchiquizam · X

RT @NEJM: New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr…

May 29, 2025 · 30 shares · 221 followers View post →
NEJM
@NEJM · X

New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://t.co/HJRCr08S8K Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://t.co/XSrLcyxVwT Upadacitinib for Giant-Cell Arteritis (SELECT-GCA phase 3 https://t.co/WSsy7mQQLV

May 29, 2025 · 116 likes · 30 shares · 936,087 followers View post →
BaladoCritique : club de lecture médical
@baladocritique.bsky.social · Bluesky

"Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death." Publié ce jour dans le @nejm.org. #MedSky www.nejm.org/doi/full/10....

May 29, 2025 View post →
ガースー＠関節系内科医
@gasu2019koto · X

3月の記事読み逃してたので今更だが、WHO分類Ⅲ,Ⅳの最大量治療してるPAHにおいて、sotaterceptが死亡・肺移植・入院の複合アウトカムを有意に改善。試験は有効性みて早期中止。 多い有害事象は毛細血管拡張と鼻出血。 https://t.co/6iOkolEa66

May 28, 2025 · 4 likes · 2,039 followers View post →
Hassan Al-Harith
@h_a_progress · X

RT @drbennisahmed: Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death treatment with sotatercept resulted…

May 23, 2025 · 1 share · 3 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening PAH https://t.co/7Xx8Kr7tkh https://t.co/pJI3W8ZsUx

May 23, 2025 · 7 likes · 1 share · 2,773 followers View post →
Juan Senior
@jsenior64 · X

Aquí les dejo el estudio. Muy interesante, un mecanismo relativamente novedoso para modular, con efecto sobre mortalidad, que en el escenario de hipertensión pulmonar no ha sido fácil. Desafortunadamente genera incertidumbre por lo expresado. https://t.co/IlVb4AuJkH

May 6, 2025 · 11,062 followers View post →
Diego
@ucedilla · X

RT @DrSamuelBHume: Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv…

Apr 28, 2025 · 2 shares · 504 followers View post →
循環器病薬剤師ネットワーク(#循薬ネット)
@Cardio_Pharm_JP · X

【対象論文】 Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death PMID: 40167274 https://t.co/kl9f3h6I3h

Apr 28, 2025 · 1 like · 4,416 followers View post →
Dr. Minoo Battiwalla
@DrBattiwalla · X

RT @DrSamuelBHume: Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv…

Apr 24, 2025 · 2 shares · 1,818 followers View post →
Samuel Hume
@DrSamuelBHume · X

Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv 5. https://t.co/TKT3xJbcDF 6. https://t.co/LCPGEEwcVZ 7. https://t.co/IazDTzuRuz 8. https://t.co/JS85pKMfaW 9. https://t.co/wdrTn03WYv 10.

Apr 24, 2025 · 40 likes · 2 shares · 29,128 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening PAH https://t.co/7Xx8Kr7tkh https://t.co/dBgKomQ6VY

Apr 21, 2025 · 3 likes · 2,773 followers View post →
世界・驚愕ニュース
@world_news2025 · X

https://t.co/ZIRSoZVBtT

Apr 13, 2025 · 2 likes · 15,868 followers View post →
ガースー＠関節系内科医
@gasu2019koto · X

Sotatercept(アクチビンシグナルを阻害するBio)が最大耐用量の既存治療が入っているPAH患者の死亡・肺移植・増悪入院の複合アウトカムをプラセボより有意に改善したP3。 有効性に差が出たので試験は早期中止。有害事象は毛細血管拡張、PLT低下、Hb上昇、鼻出血、歯肉出血程度 https://t.co/6iOkolEHVE

Apr 10, 2025 · 8 likes · 2,039 followers View post →
Smooth257
@HdR259 · X

RT @mvaduganathan: Wow!

Apr 9, 2025 · 31 shares · 193 followers View post →
Lino C M
@lcm69e · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death https://t.co/Humynw7mm2

Apr 7, 2025 · 867 followers View post →
Rafael Avila
@rafadata1 · X

RT @rafadata1: My highlights Sotatercept in severe PAH (ZENITH - NEJM): + 76% risk reduction (death/transplant/hospitalization) + Improve…

Apr 6, 2025 · 1 share · 178 followers View post →
Rafael Avila
@rafadata1 · X

My highlights Sotatercept in severe PAH (ZENITH - NEJM): + 76% risk reduction (death/transplant/hospitalization) + Improves WHO class & biomarkers − Nosebleeds, telangiectasias − Short trial, selective population Bottom line: promising add-on therapy https://t.co/qA4KbDT2lH

Apr 6, 2025 · 1 like · 1 share · 178 followers View post →
PubMed Trending
@PubTrend · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. https://t.co/DFaWc7ky3u

Apr 5, 2025 · 5,164 followers View post →
Dr Ashish Kumar
@DrAshish_Kumar · X

RT @mvaduganathan: Wow!

Apr 5, 2025 · 31 shares · 19,336 followers View post →
Carlos Ortiz Bautista
@Carlos_Ortiz85 · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 506 followers View post →
SultanSBAlSA
@SultanSBAlSA · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 45 followers View post →
HerniaHerney
@HerniaHerney · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 27 followers View post →
Abdullah Al-Abcha
@AbdullahAlabcha · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 2,259 followers View post →
PubMed Trending
@PubTrend · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. https://t.co/DFaWc7ky3u

Apr 4, 2025 · 5,164 followers View post →
Yogesh Reddy
@yreddyhf · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 1,351 followers View post →
Charles Fauvel
@CharlesFauvel · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 1,504 followers View post →
Chema Fernandez
@chemachir · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 3,835 followers View post →
Pedro Schwartzmann, MD, PhD, FESC
@pedschwartzmann · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 1,404 followers View post →
Syed Saad Mahmood, MD
@SaadMahmoodMD · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 1,105 followers View post →
Claudia Baratto
@cla_baratto · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 168 followers View post →
Riccardo Treu
@Riccardo_Treu · X

RT @mvaduganathan: Wow!

Apr 4, 2025 · 31 shares · 1 followers View post →
EOLO MORANDI JR.
@eolojr · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 540 followers View post →
Rami EdgeLord
@KhouryHopes · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 34 followers View post →
Bryan C. Taylor
@bctaylorauthor · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 413 followers View post →
Dhrub Bandyopadhyay, MD, FACP, FACC
@dhrubajyoti1 · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 628 followers View post →
Roberto M.A. Colque
@colque_roberto · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 166 followers View post →
BiykemBozkurt
@BiykemB · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 5,747 followers View post →
Takuya Kishi @ねこ好き循環器内科医
@tkishi_cardiol · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 3, 2025 · 54 shares · 14,756 followers View post →
juan ramon
@RamonTasmania · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 95 followers View post →
Ajit S Brar
@brar_cards · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 2 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening PAH https://t.co/7Xx8Kr819P https://t.co/ZxGUm94SWi

Apr 3, 2025 · 7 likes · 2,773 followers View post →
Mark Belkin
@MarkBelkinMD · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 2,456 followers View post →
Anthony Peters
@aepetersMD · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 166 followers View post →
Laura Andino, PharmD, MPH
@Andinogliflozin · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 183 followers View post →
Sarah Birkhoelzer @sarah.theheartdoc
@BirkhoelzerS · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 4,275 followers View post →
Ryan J Tedford MD
@RyanTedfordMD · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 9,716 followers View post →
Orly Leiva, MD
@LeivaOrly · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 3,809 followers View post →
Alex James, MD
@alexjamesmd · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 603 followers View post →
Henry Han
@HanCardiomd · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 16,147 followers View post →
Sarah Abou Alaiwi
@sarahaboualaiwi · X

RT @mvaduganathan: Wow!

Apr 3, 2025 · 31 shares · 2,715 followers View post →
Muthu Vaduganathan
@mvaduganathan · X

Wow!

Apr 3, 2025 · 100 likes · 31 shares · 9,245 followers View post →
Sameer Ahmed
@SameerA41115539 · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 3, 2025 · 23 shares · 997 followers View post →
Yasmin Raza
@YasminRazaMD · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 3, 2025 · 54 shares · 16 followers View post →
Jeff Langford
@JeffLangford_SC · X

RT @accpcardprn: It’s #WNW with the recently published results ZENITH in @NEJM. This study found that sotatercept was superior to placebo f…

Apr 2, 2025 · 2 shares · 111 followers View post →
Cornerstone Medical Education
@Cornerstone_CME · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 145 followers View post →
Wei-Guo Ma, MD
@Dr_Ma_of_PUMC · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 2,370 followers View post →
Maryam S. Sanjani, PhD
@MaryamSanjani · X

RT @AlbertaPHdoc: Coming out of Twitter retirement to share a very important and impactful paper published today in @NEJM : The #ZENITH tri…

Apr 2, 2025 · 29 shares · 254 followers View post →
EOLO MORANDI JR.
@eolojr · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 540 followers View post →
ACCP Cardiology PRN
@accpcardprn · X

It’s #WNW with the recently published results ZENITH in @NEJM. This study found that sotatercept was superior to placebo for high risk PAH patients on maximally tolerated background therapy. Is sotatercept the new breakthrough therapy for PAH?? https://t.co/ICF3VcTJzR

Apr 2, 2025 · 5 likes · 2 shares · 9,297 followers View post →
Dina Abbas
@dina4patients · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 13 followers View post →
markusathome
@markusathome.bsky.social · Bluesky

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death by Drs. Humbert, Hoeper et al. nejm.org/doi/full/10.... Treatment with sotatercept showed significant benefit in high-risk adults with pulmonary arterial hypertension.

Apr 2, 2025 · 2 likes · 1 share View post →
markusathome
@MarkusAtHome · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death by Drs. Humbert, Hoeper et al. https://t.co/7lOzAMc6D2 Treatment with sotatercept showed significant benefit in high-risk adults with pulmonary arterial hypertension. https://t.co/zG052kMTmr

Apr 2, 2025 · 3 likes · 118 followers View post →
Jose Marquez
@JoseMarquezCard · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Apr 2, 2025 · 10 shares · 229 followers View post →
Vinegar, MD
@Vinegar_MD · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 2, 2025 · 54 shares · 40 followers View post →
SultanSBAlSA
@SultanSBAlSA · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 2, 2025 · 54 shares · 45 followers View post →
SultanSBAlSA
@SultanSBAlSA · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 45 followers View post →
Vikas bhargava
@Vikasbh40772075 · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 3 followers View post →
Luis Caminal
@caminalm · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 965 followers View post →
Powell Kafwanka, MBChB, MSc
@PowellKafwanka · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 2, 2025 · 23 shares · 92 followers View post →
…
@Antoni0Lope3 · X

RT @CardioNotion: 5⃣

Apr 2, 2025 · 1 share · 91 followers View post →
Adnan Khan
@Adnan_KhanMD · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 2, 2025 · 54 shares · 510 followers View post →
ATS PC Assembly
@ATS_PC · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 2, 2025 · 54 shares · 1,393 followers View post →
ATS PC Assembly
@ATS_PC · X

RT @AlbertaPHdoc: Coming out of Twitter retirement to share a very important and impactful paper published today in @NEJM : The #ZENITH tri…

Apr 2, 2025 · 29 shares · 1,393 followers View post →
Berenice Torres
@PaniithoO · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 1, 2025 · 23 shares · 103 followers View post →
Peter Edmonds
@pjedmonds · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 1, 2025 · 23 shares · 898 followers View post →
Rodney Samaan
@rsamaan · X

RT @NEJM: Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of…

Apr 1, 2025 · 54 shares · 2,380 followers View post →
EOLO MORANDI JR.
@eolojr · X

RT @areciomayoral: #ACC25: Witness the #ZENITH of PAH treatment!

Apr 1, 2025 · 3 shares · 540 followers View post →
உன்னைப்போல் ஒருவன்
@vinopan007 · X

RT @NEJM: Original Article: Sotatercept in Pulmonary Arterial Hypertension with High Risk of Death (ZENITH trial) https://t.co/HJRCr08S8K…

Apr 1, 2025 · 23 shares · 230 followers View post →
旅人 tabito
@tabibito250 · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | New England Journal of Medicine https://t.co/U7stdUTXFb

Apr 1, 2025 · 1 like · 1,072 followers View post →
Javi Moreiras
@jmmoreiras · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Apr 1, 2025 · 10 shares · 3,749 followers View post →
Ana Piera #JuntosEsMasFacil
@ana_apiecar · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 2,576 followers View post →
Daniel Coyne
@DrDanMO · X

Sotatercept is an ActRIIA-IgG1 fusion protein trap molecule. It increased Hgb and improved bone in ESRD in a ph2 study (Coyne DW Ki Rep 2019). Now found a home… Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death https://t.co/jt0pWxRjJq

Mar 31, 2025 · 1 like · 3,472 followers View post →
旅人 tabito
@tabibito250 · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | New England Journal of Medicine https://t.co/U7stdUTXFb

Mar 31, 2025 · 1,072 followers View post →
Carolina Tiraplegui
@Carolina_tgel · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 380 followers View post →
Miguel A. Martín Arena
@martinarenaMA · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 578 followers View post →
CremerCardio
@CremerCardio · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 133 followers View post →
Abdelhamid Hamdy
@abdelhamed012 · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death https://t.co/LKckeKzsFJ

Mar 31, 2025 · 1 like · 3,387 followers View post →
M.Carmen Duran
@NITOSLAV · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 197 followers View post →
Marinela Chaparro
@marinelacardio · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 186 followers View post →
Michele Trichilo
@MicheleTrichil0 · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 348 followers View post →
Almudena Castro Conde
@almucastro01 · X

Hoy te contaremos en que para mí es el estudio de esta #ACC25 Zenith trial : Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death ‼️Detenido prematuramente ‼️ https://t.co/OgmEmaQIYM

Mar 31, 2025 · 11 likes · 16,060 followers View post →
Alejandro Recio
@areciomayoral · X

RT @almucastro01: IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hyp…

Mar 31, 2025 · 10 shares · 664 followers View post →
Almudena Castro Conde
@almucastro01 · X

IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Mar 31, 2025 · 35 likes · 10 shares · 16,060 followers View post →
Almudena Castro Conde
@almucastro01 · X

IMPRESIONANTES RESULTADOS del #Zenith trial detenido prematuramente: Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Mar 31, 2025 · 16,060 followers View post →
Satoshi Miyashita, MD | 宮下 智
@satoshiboston · X

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | New England Journal of Medicine https://t.co/VJAbUqwpdU

Mar 31, 2025 · 1 like · 1,990 followers View post →